Literature DB >> 8270810

Gaucher's disease: a pilot study of the symptomatic responses to enzyme replacement therapy.

C L Verderese1, O C Graham, C A Holder-McShane, N E Harnett, N W Barton.   

Abstract

Symptomatic responses to enzyme replacement therapy were studied in 12 patients with an inherited lipid storage disorder (Type 1 Gaucher's disease) in order to determine the impact of treatment on perceptions of well being. Before each intravenous infusion of enzyme, patients were asked to comment on the presence or absence of disease-specific symptoms presented in questionnaire format. Symptoms were grouped into five major categories: bleeding abnormalities, chronic fatigue, gastrointestinal complaints, bone pain and psychosocial function. Each reported symptom was discussed in detail with the clinic nurse coordinator and documented in the medical record. After six months of enzyme replacement therapy, each patient's chart was reviewed and changes in the frequency of disease-specific symptoms over time were evaluated. The major subjective changes included a decrease in the frequency and severity of nosebleeds, reduced bruising, increased vigor and energy level, visible reduction in abdominal girth, increased self-esteem and enhanced self-image. Patients frequently described relief of their symptoms well before changes were confirmed by objective laboratory measurements. These observations may prove useful in the comprehensive management of patients with Gaucher's disease as they recover from a chronic, debilitating illness while receiving enzyme replacement therapy. The extent and ease with which these patients can achieve a state of normal, healthy function is unknown at the present time and will require further study.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8270810     DOI: 10.1097/01376517-199310000-00005

Source DB:  PubMed          Journal:  J Neurosci Nurs        ISSN: 0888-0395            Impact factor:   1.230


  5 in total

1.  Urge incontinence and gastrointestinal symptoms in adult patients with pompe disease: a cross-sectional survey.

Authors:  Nesrin Karabul; Anika Skudlarek; Janine Berndt; Cornelia Kornblum; Rudolf A Kley; Stephan Wenninger; Nikolaus Tiling; Eugen Mengel; Ursula Plöckinger; Matthias Vorgerd; Marcus Deschauer; Benedikt Schoser; Frank Hanisch
Journal:  JIMD Rep       Date:  2014-08-26

2.  The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study.

Authors:  A M Damiano; G M Pastores; J E Ware
Journal:  Qual Life Res       Date:  1998-07       Impact factor: 4.147

Review 3.  Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease.

Authors:  R Whittington; K L Goa
Journal:  Pharmacoeconomics       Date:  1995-01       Impact factor: 4.981

4.  The impact of Gaucher disease and its treatment on quality of life.

Authors:  R P Hayes; K A Grinzaid; E B Duffey; L J Elsas
Journal:  Qual Life Res       Date:  1998-08       Impact factor: 4.147

Review 5.  Rethinking fatigue in Gaucher disease.

Authors:  Y Chen Zion; E Pappadopulos; M Wajnrajch; H Rosenbaum
Journal:  Orphanet J Rare Dis       Date:  2016-04-29       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.